Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel F Hayes

Showing results (221-230 of 336) with videos related to

Pageof 34
Sort By:
Breast Cancer Research and Treatment|June 8, 2015
Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancerMegan E V Caram, Cui Guo, Monika Leja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2016
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineLyndsay N Harris, Nofisat Ismaila, Lisa M McShane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2023
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 TrialCorey W Speers, W Fraser Symmans, William E Barlow, et al.
British Journal of Clinical Pharmacology|December 12, 2019
Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathyLauren A Marcath, Kelley M Kidwell, Kiran Vangipuram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancerRachel M Layman, Dafydd G Thomas, Kent A Griffith, et al.
Archives of Pathology & Laboratory Medicine|October 2, 2009
Protocol for the examination of specimens from patients with invasive carcinoma of the breastSusan C Lester, Shikha Bose, Yunn-Yi Chen, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 23, 2003
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cellsCelina G Kleer, Qi Cao, Sooryanarayana Varambally, et al.
NPJ Breast Cancer|August 26, 2017
Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancerCorey Speers, Shuang G Zhao, Ben Chandler, et al.
Breast Cancer Research and Treatment|April 3, 2013
Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancerN Lynn Henry, Todd C Skaar, Jessica Dantzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500Jeffrey B Smerage, William E Barlow, Gabriel N Hortobagyi, et al.
Pageof 34

Showing results (221-230 of 336) with videos related to

Sort By:
Pageof 34
Breast Cancer Research and Treatment|June 8, 2015
Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancerMegan E V Caram, Cui Guo, Monika Leja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2016
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineLyndsay N Harris, Nofisat Ismaila, Lisa M McShane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2023
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 TrialCorey W Speers, W Fraser Symmans, William E Barlow, et al.
British Journal of Clinical Pharmacology|December 12, 2019
Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathyLauren A Marcath, Kelley M Kidwell, Kiran Vangipuram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancerRachel M Layman, Dafydd G Thomas, Kent A Griffith, et al.
Archives of Pathology & Laboratory Medicine|October 2, 2009
Protocol for the examination of specimens from patients with invasive carcinoma of the breastSusan C Lester, Shikha Bose, Yunn-Yi Chen, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 23, 2003
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cellsCelina G Kleer, Qi Cao, Sooryanarayana Varambally, et al.
NPJ Breast Cancer|August 26, 2017
Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancerCorey Speers, Shuang G Zhao, Ben Chandler, et al.
Breast Cancer Research and Treatment|April 3, 2013
Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancerN Lynn Henry, Todd C Skaar, Jessica Dantzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500Jeffrey B Smerage, William E Barlow, Gabriel N Hortobagyi, et al.
Pageof 34